Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Part of paid clinical trials in San Francisco, California.

Sponsor
Children's Hospital of Philadelphia
Study ID
NCT06156410
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Ewing Sarcoma
  • Osteosarcoma
  • Sarcomas

Eligibility Criteria

Sex
ALL
Age
5 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Cabozantinib — DRUG
    Participants will receive cabozantinib in combination with high-dose ifosfamide for 5 cycles. If still on study therapy the participants will continue with cabozantinib monotherapy for up to 12 total cycles.

Study Details

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.

Key Dates

Start date
Oct 24, 2023
Status verified
Nov 2025
Primary completion
Nov 30, 2027
Completion
Nov 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Cabozantinib

Primary Outcome Measure

Maximum tolerated dose/recommended phase II dose (MTD/RP2D) of cabozantinib [ Time Frame: Upon completion of accrual to phase 1 cohort, approximately 1 year ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
University of California San FranciscoSan FranciscoCalifornia94143
Amanda Marinoff, MD
Children's Hospital ColoradoAuroraColorado80045
Emily Blauel, MD
[email protected]
720-777-6978
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104
Shelby Brizzolara Dove
[email protected]
267-425-2187
University of PennsylvaniaPhiladelphiaPennsylvania19104
Daniel Lefler, MD
[email protected]
215-829-7089

Find similar trials in San Francisco, CA

By research site
University of California San Francisco· San Francisco, CAChildren's Hospital Colorado· Aurora, COChildren's Hospital of Philadelphia· Philadelphia, PAUniversity of Pennsylvania· Philadelphia, PA

Related Studies